SIGN UP FOR OUR
E-NEWSLETTER
INTERCEPT eNews delivers product news & information updates. 
Product News
INTERCEPT Treatment of Platelets Suspended in SSP+ Additive Solution
Platelet concentrates suspended in SSP+ additive solution can now be treated with any of the INTERCEPT Platelet processing sets. Combined with the May 2009 approval to treat platelets suspended in 100% plasma, this SSP+ approval further broadens INTERCEPT's compatibility with platelet collection practices. This label expansion has been approved by our Notified Body, TÜV SÜD Product Service. SSP+, manufactured by MacoPharma, Mouvaux, France is a CE Marked commercially available platelet additive solution (PAS) designed to partially replace plasma in apheresis and buffy coat platelet collections; it is a modification to the third generation PAS formulation (PAS-IIIM).
Cerus has completed the requisite in vitro testing to verify that INTERCEPT is effective for platelets suspended in SSP+.
Cerus is committed to providing quality products and services, and is pleased to announce this label claim expansion to allow customers a choice of platelet additive solution.
Related information:
Updated Processing Range Requirements
Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Website design by NetPilot Web Solutions